The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms
Open accessAbstract
The incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26 million people suffering from CKD in the United States alone. More patients with CKD die of cardiovascular complications than progress to dialysis. Over 80% of CKD patients have hypertension, which is associated with increased risk of cardiovascular morbidity and mortality. Another common, perhaps underappreciated, feature of CKD is an overactive sympathetic nervous system. This elevation in sympathetic nerve activity (SNA) not only contributes to hypertension but also plays a detrimental role in the progression of CKD independent of any increase in blood pressure. Indeed, high SNA is associated with poor prognosis and increased cardiovascular morbidity and mortality independent of its effect on blood pressure. This brief review will discuss some of the consequences of sympathetic overactivity and highlight some of the potential pathways contributing to chronically elevated SNA in CKD. Mechanisms leading to chronic sympathoexcitation in CKD are complex, multifactorial and to date, not completely understood. Identification of the mechanisms and/or signals leading to sympathetic overactivity in CKD are crucial for development of effective therapeutic targets to reduce the increased cardiovascular risk in this patient group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Original record of muscle sympathetic nerve activity (MSNA) in a normal subject and a renal failure patient on hemodialysis, demonstrating significantly greater resting MSNA in the dialysis patient. The bottom two panels display a portion of the neurogram and simultaneous electrocardiogram from the patient on hemodialysis showing that the renal failure patient has a burst of MSNA with every cardiac cycle. (Modified from Converse et al. [11] with permission).](https://figures.cochat.ai/paper-figures/c29f315edad14e6d80676416128a09dc/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-1.jpg)
![Figure 2 Muscle sympathetic nerve activity (MSNA) expressed as burst frequency (bursts (bs)/min, A) and burst incidence (bs/100 heartbeats (hb), B) in subjects grouped according to their estimated glomerular filtration rate (eGFR), with the highest quartile of eGFR in group I and lowest quartile of eGFR in group IV. With decreasing eGFR, there is a significant and progressive increase in resting MSNA in chronic kidney disease (CKD) patients. * p < 0.05 significant difference between quartiles. (From Grassi et al. [13] with permission).](https://figures.cochat.ai/paper-figures/b4ac89c6b0474f7ca430dc2de3b4c6dc/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-2.jpg)
![Figure 3 Mean arterial pressure (MAP) responses during 8-h continuous systemic infusion of the nitric oxide synthase (NOS) inhibitor l-nitroarginine methyl ester (l-NAME) in rats with sympathectomy (open circles) and without sympathectomy (closed circles). Although no difference was observed in the initial increase in MAP (removal of endothelium-mediated dilation), sympathectomy attenuated the sustained hypertensive response to l-NAME, demonstrating a sympathetic contribution to the blood pressure raising effects of systemic NOS inhibition. * p < 0.05 vs. control. (From Sander et al. [75] with permission).](https://figures.cochat.ai/paper-figures/c4fa82d6798d4656876e51594ce8db56/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-3.jpg)
![Figure 4 Average mean arterial pressure, heart rate, and renal sympathetic nerve activity during continuous systemic infusion of asymmetric dimethylarginine (ADMA; an endogenous NOS inhibitor) in baroreceptor-intact (A) and baroreceptor-denervated animals (B). In comparison with barointact animals, barodenervated animals show a significant increase in renal SNA indicating frank sympathoexcitation in response to systemic ADMA infusion. * p < 0.05 vs. baseline; † p < 0.05 vs. baroreceptor intact. (From Augutyniak et al. [87] with permission.)](https://figures.cochat.ai/paper-figures/c6752938f9484a64b8856be4cf6b53c4/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Elevated sympathetic nerve activity is a hallmark of CKD104 that is evident even in the early stages of the disease and correlates inversely with estimated glomerular filtration rate (eGFR) and disease progression105.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [104]
In the citing paper
“The occur-rence of increased SNS activity in hypertension and CKD is well established83,162.”
From The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease (2018) · cites this paper as [162]
In the citing paper
“Modulation of the gut microbiota reduces systemic inflammation and SNS activity, both of which contribute to hypertension and CKD80,162,208.”
From The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease (2018) · cites this paper as [162]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895 · cited 1×
“More than 26 million people in the United States suffer from chronic kidney disease (CKD) with thousands of new cases diagnosed each year [1].”
Background(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 1×
“Moderate to severe CKD (stage 3–5) is associated with a significantly higher risk of cardiovascular (CV) morbidity and mortality [4,5].”
BackgroundAngiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Physiological aspects of primary hypertension.
Folkow, B. (1982) · Physiological Reviews · doi:10.1152/physrev.1982.62.2.347 · Cited by 1,768
Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Cited by
The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
Yang, T., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0018-2 · Cited by 753
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Baaten, C. C. F. M. J., Vondenhoff, S., & Noels, H. (2023) · Circulation Research · doi:10.1161/circresaha.123.321752 · Cited by 243
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Sano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.12.004 · Cited by 188
Querfeld, U., MAK, R. H. K., & Pries, A. R. (2020) · Clinical Science · doi:10.1042/cs20200279 · Cited by 152
Metadata
- Authors
- Kaur, J., Young, B., & Fadel, P.
- Affiliations
- The University of Texas at Arlington (US)
- Corresponding author
- Fadel, Paul
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-08-02
- Volume
- 18
- Issue
- 8
- Pages
- 1682
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5578072
- OpenAlex
- W2741868536
- Cited by
- 168
- References
- 156
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 25 · 2023: 14 · 2022: 17 · 2021: 23 · 2020: 16 · 2019: 16 · 2018: 9 · 2017: 1
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NIH R01 HL127071)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- chronic kidney disease, sympathetic nervous system, sympathoexcitation, sympathetic activity, hypertension, cardiovascular risk, chronic kidney disease progression, cardiovascular mortality, therapeutic target
- MeSH terms
- Animals, Humans, Hypertension, Renal, Sympathetic Nervous System, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. https://app.cochat.ai/papers/10.3390/ijms18081682
- The paper
- Kaur, J., Young, B., & Fadel, P. (2017). Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18081682
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.